Michael J. Carson - 06 Jan 2026 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Jan 2026, 16:30:17 UTC
Prior SEC filing
03 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Michael Carson

Key filing fact

Michael J. Carson filed Form 4 for Nuvectis Pharma, Inc. (NVCT) on 09 Jan 2026.

Key facts

  • This page summarizes Michael J. Carson's Form 4 filing for Nuvectis Pharma, Inc. (NVCT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 09 Jan 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 03 Jan 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001896079 Primary reporting owner

Carson Michael J.

Relationship
Vice President, Finance
Address
C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE
Signature
/s/ Michael Carson
Signature date
09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCT transaction

Common Stock

Award

Transaction value
$0
Shares
+61,200
Change %
+44%
Price
$0.000000
Shares after
200,118
Date
06 Jan 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The 61,200 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates.

Footnote F2

Includes shares of restricted common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .